Clinical Trial News and Research

RSS

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.

30 Jan 2014

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.

30 Jan 2014

Johnson & Johnson enters into novel agreement with YODA to share clinical trials data

Johnson & Johnson today announced that its subsidiary, Janssen Research and Development, LLC, has entered into a novel agreement with Yale School of Medicine's Open Data Access (YODA) Project that will extend its commitment to sharing clinical trials data to enhance public health and advance science and medicine.

30 Jan 2014

Vaccine to treat precancerous cervical lesions triggers immune cell response

Preliminary results of a small clinical trial show that a vaccine used to treat women with high-grade precancerous cervical lesions triggers an immune cell response within the damaged tissue itself.

30 Jan 2014

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine).

30 Jan 2014

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Researchers led by Marta Barrachina, Institute of Neuropathology of the Bellvitge Biomedical Research Institute (IDIBELL) have identified a new subgroup of patients suffering from schizophrenia characterized by motor disorders.

29 Jan 2014

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Omeros Corporation today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.

29 Jan 2014

NIBIB-funded researchers develop microscopic technique to improve Mohs surgery

A common surgery for non-melanoma skin cancer, known as Mohs surgery typically achieves excellent results but can be a long process, as the surgeon successively removes the area of concern until the surrounding tissue is free of cancer.

29 Jan 2014

Researchers identify unique area of human brain associated with cognitive powers

Oxford University researchers have identified an area of the human brain that appears unlike anything in the brains of some of our closest relatives.

29 Jan 2014

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it will announce the results of its Phase 2a clinical trial for the company's ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes on January 30, 2014.

28 Jan 2014

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Cell Therapeutics, Inc.today announced that the Gynecologic Oncology Group informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer.

28 Jan 2014

Researchers identify therapeutic target for cervix cancer

Gene related to the proliferation of cancerous cells blocked through molecular technology. A group of researchers from Mexico's General Hospital, Health Secretariat, Medicine Faculty and the Institute of Cellular Physiology of the National Autonomous University of Mexico (UNAM) identified a therapeutic target for cervix cancer: gene CDKN3.

28 Jan 2014

Scientists produce new version of old antibiotic that is active against difficult-to-treat tuberculosis

St. Jude Children's Research Hospital scientists have discovered a promising new class of antibiotics that could aid efforts to overcome drug-resistance in tuberculosis (TB), a global killer.

28 Jan 2014

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Pfizer Inc. today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer.

28 Jan 2014

BioTime: OncoCyte initiates clinical development of bladder cancer diagnostic test in U.S, China

BioTime, Inc. and its subsidiary OncoCyte Corporation today announced that OncoCyte has initiated clinical development of its bladder cancer diagnostic test in both the United States and China.

28 Jan 2014

Tufts Medical Center receives funds to develop mathematical models to identify patients for clinical trials

A Tufts Medical Center research team at the Institute for Clinical Research and Health Policy Studies (ICRHPS) has been approved for a funding award by the Patient-Centered Outcomes Research Institute (PCORI) to develop a method for patient-centered enrollment in comparative effectiveness trials called Mathematical Equipoise.

28 Jan 2014

New versions of old antibiotic offers strategy for overcoming drug resistance

Research led by St. Jude Children's Research Hospital scientists has produced new versions of an old antibiotic that are active against difficult-to-treat tuberculosis; offers new strategy for overcoming drug resistance

28 Jan 2014

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

Scientists have begun the first human clinical trial of EDP-788, an investigational oral antibiotic intended to treat methicillin-resistant Staphylococcus aureus (MRSA) infections.

27 Jan 2014

Practicing yoga for atleast 3 months can reduce fatigue and inflammation in breast cancer survivors

Practicing yoga for as little as three months can reduce fatigue and lower inflammation in breast cancer survivors, according to new research.

27 Jan 2014

Myelin Repair Foundation enters into agreement with NIH to assess MRF-008 for multiple sclerosis

The Myelin Repair Foundation today announced it has entered a Cooperative Research and Development Agreement with the National Institutes of Health to assess MRF-008, as a potential therapeutic for multiple sclerosis. This CRADA will facilitate collaboration between the MRF and National Institute of Neurological Disorders and Stroke at the NIH Clinical Center to study MRF-008, a drug identified by the MRF as a potential neuroprotective therapeutic to enhance repair in multiple sclerosis patients.

27 Jan 2014

Clinical Trial News and Research

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Johnson & Johnson enters into novel agreement with YODA to share clinical trials data

Vaccine to treat precancerous cervical lesions triggers immune cell response

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

NIBIB-funded researchers develop microscopic technique to improve Mohs surgery

Researchers identify unique area of human brain associated with cognitive powers

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Researchers identify therapeutic target for cervix cancer

Scientists produce new version of old antibiotic that is active against difficult-to-treat tuberculosis

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

BioTime: OncoCyte initiates clinical development of bladder cancer diagnostic test in U.S, China

Tufts Medical Center receives funds to develop mathematical models to identify patients for clinical trials

New versions of old antibiotic offers strategy for overcoming drug resistance

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

Practicing yoga for atleast 3 months can reduce fatigue and inflammation in breast cancer survivors

Myelin Repair Foundation enters into agreement with NIH to assess MRF-008 for multiple sclerosis

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer